Technical Analysis for RDY - Dr. Reddy's Laboratories Ltd

Grade Last Price % Change Price Change
grade B 35.29 -3.92% -1.44
RDY closed down 3.92 percent on Friday, September 21, 2018, on 1.24 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical RDY trend table...

Date Alert Name Type % Chg
Sep 21 Fell Below 20 DMA Bearish 0.00%
Sep 21 MACD Bearish Signal Line Cross Bearish 0.00%
Sep 21 Stochastic Sell Signal Bearish 0.00%
Sep 21 Slingshot Bullish Bullish Swing Setup 0.00%
Sep 21 Overbought Stochastic Strength 0.00%
Sep 21 Gapped Down Weakness 0.00%
Sep 20 MACD Bullish Signal Line Cross Bullish -3.92%
Sep 20 New Uptrend Bullish -3.92%
Sep 20 Overbought Stochastic Strength -3.92%
Sep 20 Up 3 Days in a Row Strength -3.92%

Older signals for RDY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in the operation of biologics business. The Proprietary Products segment engages in the discovery and development of new chemical entities for subsequent commercialization and out-licensing. It offers new, synergistic combination, and technology formulations that modifies pharmacokinetics of existing medicines. This segment is also involved in the Company's specialty pharmaceuticals business that includes sales and marketing operations for in-licensed and co-developed dermatology. The company offers its products and services primarily in the areas of gastrointestinal, cardiovascular, pain management, and oncology therapies. It primarily operates in India, the United States, Russia and other countries of the former Soviet Union, Europe, and others. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Is RDY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 39.96
52 Week Low 28.13
Average Volume 294,842
200-Day Moving Average 33.4992
50-Day Moving Average 33.295
20-Day Moving Average 35.3655
10-Day Moving Average 35.699
Average True Range 0.6656
ADX 24.28
+DI 37.3936
-DI 28.9515
Chandelier Exit (Long, 3 ATRs ) 34.8132
Chandelier Exit (Short, 3 ATRs ) 35.4718
Upper Bollinger Band 36.8157
Lower Bollinger Band 33.9153
Percent B (%b) 0.47
BandWidth 8.201213
MACD Line 0.6833
MACD Signal Line 0.7438
MACD Histogram -0.0605
Fundamentals Value
Market Cap 5.85 Billion
Num Shares 166 Million
EPS 1.07
Price-to-Earnings (P/E) Ratio 32.98
Price-to-Sales 2.69
Price-to-Book 3.07
PEG Ratio 0.00
Dividend 0.31
Dividend Yield 0.88%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.15
Resistance 3 (R3) 36.23 36.04 36.00
Resistance 2 (R2) 36.04 35.82 35.99 35.95
Resistance 1 (R1) 35.66 35.68 35.57 35.58 35.91
Pivot Point 35.47 35.47 35.42 35.42 35.47
Support 1 (S1) 35.09 35.25 35.00 35.01 34.67
Support 2 (S2) 34.90 35.11 34.85 34.63
Support 3 (S3) 34.52 34.90 34.58
Support 4 (S4) 34.44